PL331148A1 - Novel method of treating the leptin immunity - Google Patents

Novel method of treating the leptin immunity

Info

Publication number: PL331148A1
Authority: PL; Poland
Prior art keywords: leptin; immunity; treating; novel method; novel
Prior art date: 1996-07-12

Application number

PL97331148A

Inventor

George Henry Poste

Stephen Alistair Smith

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-12

Filing date

1997-07-14

Publication date

1999-06-21

1996-07-12 Priority claimed from GBGB9614740.0A external-priority patent/GB9614740D0/en

1996-07-12 Priority claimed from GBGB9614751.7A external-priority patent/GB9614751D0/en

1996-08-05 Priority claimed from GBGB9616409.0A external-priority patent/GB9616409D0/en

1996-08-05 Priority claimed from GBGB9616412.4A external-priority patent/GB9616412D0/en

1996-08-05 Priority claimed from GBGB9616407.4A external-priority patent/GB9616407D0/en

1997-07-14 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1999-06-21 Publication of PL331148A1 publication Critical patent/PL331148A1/en

Links

102000016267 Leptin Human genes 0.000 title 1
108010092277 Leptin Proteins 0.000 title 1
230000036039 immunity Effects 0.000 title 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title 1
229940039781 leptin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Peptides Or Proteins (AREA)

PL97331148A 1996-07-12 1997-07-14 Novel method of treating the leptin immunity PL331148A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9614740.0A GB9614740D0 (en)	1996-07-12	1996-07-12	Novel treatment
GBGB9614751.7A GB9614751D0 (en)	1996-07-12	1996-07-12	Novel treatment
GBGB9616409.0A GB9616409D0 (en)	1996-08-05	1996-08-05	Novel treatment
GBGB9616412.4A GB9616412D0 (en)	1996-08-05	1996-08-05	Novel treatment
GBGB9616407.4A GB9616407D0 (en)	1996-08-05	1996-08-05	Novel treatment

Publications (1)

Publication Number	Publication Date
PL331148A1 true PL331148A1 (en)	1999-06-21

Family

ID=27517363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL97331148A PL331148A1 (en)	1996-07-12	1997-07-14	Novel method of treating the leptin immunity

Country Status (12)

Country	Link
EP (1)	EP0921798A1 (en)
JP (1)	JP2000514807A (en)
KR (1)	KR20000023719A (en)
CN (1)	CN1230114A (en)
AU (1)	AU3552697A (en)
BR (1)	BR9710272A (en)
CA (1)	CA2260044A1 (en)
NO (1)	NO990097D0 (en)
PL (1)	PL331148A1 (en)
TR (1)	TR199900056T2 (en)
TW (1)	TW442288B (en)
WO (1)	WO1998002159A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9711683D0 (en) *	1997-06-05	1997-08-06	Smithkline Beecham Plc	Composition
WO1999044598A2 (en) *	1998-03-03	1999-09-10	Board Of Regents, The University Of Texas System	Methods for inhibiting βcell apoptosis
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
PL351987A1 (en)	1999-04-28	2003-07-14	Reddys Lab Ltd Dr	Substitution bicyclic-heterocyclic compounds, method of obtaining thereof, and use of such compounds to control adiposis and to reduce the level of cholesterol
ES2248581T3 (en)	2001-03-12	2006-03-16	Intercept Pharmaceuticals, Inc.	STEROIDS AS FXR AGONISTS.
WO2002080936A1 (en) *	2001-04-04	2002-10-17	Ortho Mcneil Pharmaceutical, Inc.	Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
US6987123B2 (en)	2001-07-26	2006-01-17	Cadila Healthcare Limited	Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7618940B2 (en) *	2002-12-06	2009-11-17	Fibrogen, Inc.	Fat regulation
US10987362B2 (en)	2004-03-12	2021-04-27	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using FXR ligands
PL1734970T3 (en)	2004-03-12	2015-05-29	Intercept Pharmaceuticals Inc	Treatment of fibrosis using fxr ligands
ITMI20050912A1 (en)	2005-05-19	2006-11-20	Erregierre Spa	PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
KR101555716B1 (en)	2007-01-19	2015-09-25	인터셉트 파마슈티컬즈, 인크.	5 23- 23-substituted bile acids as tgr5 modulators and methods of use thereof
WO2010014836A2 (en)	2008-07-30	2010-02-04	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
DK2698375T3 (en)	2008-11-19	2018-05-28	Intercept Pharmaceuticals Inc	TGR5 modulators and methods for using them
SI3336097T1 (en)	2012-06-19	2021-07-30	Intercept Pharmaceuticals, Inc.	Preparation of the non-crystalline form of obeticholic acid
US9982008B2 (en)	2012-06-19	2018-05-29	Intercept Pharmaceuticals, Inc.	Preparation and uses of obeticholic acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6051189A (en) *	1983-08-30	1985-03-22	Sankyo Co Ltd	Thiazolidine derivative and its preparation
US5900435A (en) *	1991-08-26	1999-05-04	Pharmacia & Upjohn Company	Composition, food product and uses of 3-guanidinopropionic acid
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds

1997
- 1997-07-14 EP EP97931945A patent/EP0921798A1/en not_active Withdrawn
- 1997-07-14 TR TR1999/00056T patent/TR199900056T2/en unknown
- 1997-07-14 CA CA002260044A patent/CA2260044A1/en not_active Abandoned
- 1997-07-14 JP JP10505759A patent/JP2000514807A/en active Pending
- 1997-07-14 CN CN97197722A patent/CN1230114A/en active Pending
- 1997-07-14 BR BR9710272A patent/BR9710272A/en unknown
- 1997-07-14 PL PL97331148A patent/PL331148A1/en unknown
- 1997-07-14 AU AU35526/97A patent/AU3552697A/en not_active Abandoned
- 1997-07-14 WO PCT/GB1997/001928 patent/WO1998002159A1/en not_active Ceased
- 1997-07-15 TW TW086110187A patent/TW442288B/en active
1999
- 1999-01-11 KR KR1019997000179A patent/KR20000023719A/en not_active Withdrawn
- 1999-01-11 NO NO990097A patent/NO990097D0/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1230114A (en)	1999-09-29
NO990097L (en)	1999-01-11
KR20000023719A (en)	2000-04-25
AU3552697A (en)	1998-02-09
TW442288B (en)	2001-06-23
CA2260044A1 (en)	1998-01-22
TR199900056T2 (en)	1999-04-21
NO990097D0 (en)	1999-01-11
BR9710272A (en)	1999-08-10
JP2000514807A (en)	2000-11-07
EP0921798A1 (en)	1999-06-16
WO1998002159A1 (en)	1998-01-22

Publication	Publication Date	Title
ZA977564B (en)	1999-02-22	Method of treatment
ZA965088B (en)	1997-01-22	Methods of preventing or treating allergles
GB2319796B (en)	2001-08-15	Formation treatment method using deformable particles
GB9600464D0 (en)	1996-03-13	Novel method
ZA971709B (en)	1998-08-27	Method of increasing testosterone
PL334012A1 (en)	2000-01-31	Novel method of treating the arthritis
PL331148A1 (en)	1999-06-21	Novel method of treating the leptin immunity
GB9605828D0 (en)	1996-05-22	Treatment method
GB2359316B (en)	2001-10-17	Formation treatment method using deformable particles
ZA973988B (en)	1998-11-09	Method of treatment
GB9618341D0 (en)	1996-10-16	Method of treatment
GB9415902D0 (en)	1994-09-28	Method of treatment
GB9604465D0 (en)	1996-05-01	Novel method
GB9407335D0 (en)	1994-06-08	Method of treatment
KR970006505B1 (en)	1997-04-28	Waste treatment method
GB9414652D0 (en)	1994-09-07	Method of treatment
GB9600888D0 (en)	1996-03-20	Method of treatment
GB9614743D0 (en)	1996-09-04	Treatment method
GB9600610D0 (en)	1996-03-13	Treatment method
GB9614741D0 (en)	1996-09-04	Treatment method
GB9614742D0 (en)	1996-09-04	Treatment method
GB9602404D0 (en)	1996-04-03	Methods of treatment
GB9412456D0 (en)	1994-08-10	Treatment method
GB9412134D0 (en)	1994-08-10	Treatment method
GB9417504D0 (en)	1994-10-19	Treatment method